BioSpace News Archive

Sunesis Pharmaceuticals, Inc. announced that it will host a conference call on Tuesday, November 12th, 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the third quarter ended September 30, 2019..

Menlo Therapeutics Inc. announced that it has completed enrollment of patients in its two Phase 3 clinical trials evaluating the safety and efficacy of once daily oral serlopitant for the treatment of pruritus associated with prurigo nodularis The U.S. and European Phase 3 trials enrolled 285 and 295 patients, respectively.

NGM Biopharmaceuticals, Inc., a clinical stage biotechnology company focused on developing transformative therapeutics for patients, announced the appointment of Valerie Pierce as Senior Vice President, General Counsel and Chief Compliance Officer.

Protalix BioTherapeutics, Inc. announced that it will release its financial results for the third quarter 2019 and business update on Thursday, November 7th, 2019.

REGENXBIO Inc. announced that it will host a conference call on Tuesday, November 5, 2019, at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2019, and recent operational highlights.

Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced the appointment of Nigel Crockett, Ph.D., as the company’s Chief Business Officer, replacing Peter Leone.

Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, announced the presentation of a development update and validation data for its cutaneous squamous cell carcinoma prognostic test, DecisionDx®-SCC.

CROs eliminating manual processes and modernizing systems to streamline information exchange and accelerate study start-up

Renowned Genetics Researcher Dr. Michael Hayden Appointed Scientific Advisory Board Chair

IMV Inc., a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, announced that it will hold a conference call and webcast on Friday, November 8, 2019 at 8:00 a.m. ET to discuss the company’s third quarter 2019 financial and operational results.